Cargando…

Digital Therapeutics: Emerging New Therapy for Nonalcoholic Fatty Liver Disease

The increased prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide is particularly worrisome, as no medication has been approved to treat the disease. Lifestyle modifications aimed at promoting weight loss and weight maintenance remain the current first-line treatment for NAFLD. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Run, Gu, Yunpeng, Zhang, Binbin, Kong, Tingting, Zhang, Wei, Li, Jie, Shi, Junping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132718/ https://www.ncbi.nlm.nih.gov/pubmed/36854062 http://dx.doi.org/10.14309/ctg.0000000000000575

Ejemplares similares

Barriers and enabling factors in weight management of patients with nonalcoholic fatty liver disease: A qualitative study using the COM‐B model of behaviour
por: Gu, Yunpeng, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine
por: Shi, Tingting, et al.
Publicado: (2020)

Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease
por: Huang, Yuanshe, et al.
Publicado: (2022)

Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options
por: Tanase, Daniela Maria, et al.
Publicado: (2020)

Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease
por: Durazzo, Marilena, et al.
Publicado: (2012)

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
por: Gu, Yunpeng, et al.
Publicado: (2023)

Combination Therapies for Nonalcoholic Fatty Liver Disease
por: Makri, Evangelia S., et al.
Publicado: (2022)

The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
por: Huang, Yue Ye, et al.
Publicado: (2013)

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications
por: Andronescu, Craita Isabela, et al.
Publicado: (2018)

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
por: Yu, Yao, et al.
Publicado: (2018)

Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
por: Mijangos-Trejo, Alejandra, et al.
Publicado: (2023)

Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats
por: Liu, Boyan, et al.
Publicado: (2020)

Emerging role of engineered exosomes in nonalcoholic fatty liver disease
por: Ding, Jian, et al.
Publicado: (2023)

Periodontal disease–related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral‐liver axis
por: Kuraji, Ryutaro, et al.
Publicado: (2021)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Erratum: The p66shc-Mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease
por: Chen, Wei, et al.
Publicado: (2018)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
por: Fang, Jie, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao, Yuqing, et al.
Publicado: (2016)

Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
por: Chang, Xinxia, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease: new treatments
por: Hardy, Timothy, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease
por: Wang, Nan, et al.
Publicado: (2017)

New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk
por: Liu, Chenan, et al.
Publicado: (2023)

Macrophage metabolism in nonalcoholic fatty liver disease
por: Zhang, Wenhui, et al.
Publicado: (2023)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
por: Marchisello, Simona, et al.
Publicado: (2019)

Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications
por: Kizivat, Tomislav, et al.
Publicado: (2020)

Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
por: Sousa-Lima, Inês, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications
por: Sotiropoulou, Maria, et al.
Publicado: (2021)

Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
por: Huang, Xiaojing, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
por: Masuoka, Howard C, et al.
Publicado: (2013)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population
por: Wang, Jinghua, et al.
Publicado: (2015)

Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds
por: Zhang, Binbin, et al.
Publicado: (2023)

New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans
por: Inzaugarat, María Eugenia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g9svr7os2kvpgqcfidmuccja0d